Merck & Co. (MRK) — insider trading
Health Care · NYSE
Merck & Co. (MRK) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-06-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Coe Mary Ellen | Director | Grant / award / vesting (derivative) | 233 | $128.50 | $30.0K | Form 4 |
| 2026-06-30 | Karsanbhai Surendralal Lanca | Director | Grant / award / vesting (derivative) | 126 | $128.50 | $16.2K | Form 4 |
| 2026-06-30 | Seidman Christine E | Director | Grant / award / vesting (derivative) | 63 | $128.50 | $8.1K | Form 4 |
| 2026-05-29 | LAVIZZO-MOUREY RISA J | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Mayo Stephen | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Rothman Paul | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | RUSSO PATRICIA F | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Seidman Christine E | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | THULIN INGE G | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Coe Mary Ellen | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Karsanbhai Surendralal Lanca | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Warden Kathy J | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
Ask the chat about MRK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Merck & Co. (MRK).
Last updated 2026-06-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.